Cargando…

Detection of SARS-CoV-2 variants by Abbott molecular, antigen, and serological tests

BACKGROUND: : Viral diversity presents an ongoing challenge for diagnostic tests, which need to accurately detect all circulating variants. The Abbott Global Surveillance program monitors severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants and their impact on diagnostic test perfor...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodgers, Mary A, Olivo, Ana, Harris, Barbara J, Lark, Chris, Luo, Xinxin, Berg, Michael G, Meyer, Todd V, Mohaimani, Aurash, Orf, Gregory S, Goldstein, Yitz, Fox, Amy S, Hirschhorn, Julie, Glen, William B, Nolte, Frederick, Landay, Alan, Jennings, Cheryl, Moy, James, Servellita, Venice, Chiu, Charles, Batra, Rahul, Snell, Luke B, Nebbia, Gaia, Douthwaite, Sam, Tanuri, Amilcar, Singh, Lavanya, de Oliveira, Tulio, Ahouidi, Ambroise, Mboup, Souleymane, Cloherty, Gavin A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Abbott Laboratories. Published by Elsevier B.V. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770247/
https://www.ncbi.nlm.nih.gov/pubmed/35086043
http://dx.doi.org/10.1016/j.jcv.2022.105080
_version_ 1784635326667423744
author Rodgers, Mary A
Olivo, Ana
Harris, Barbara J
Lark, Chris
Luo, Xinxin
Berg, Michael G
Meyer, Todd V
Mohaimani, Aurash
Orf, Gregory S
Goldstein, Yitz
Fox, Amy S
Hirschhorn, Julie
Glen, William B
Nolte, Frederick
Landay, Alan
Jennings, Cheryl
Moy, James
Servellita, Venice
Chiu, Charles
Batra, Rahul
Snell, Luke B
Nebbia, Gaia
Douthwaite, Sam
Tanuri, Amilcar
Singh, Lavanya
de Oliveira, Tulio
Ahouidi, Ambroise
Mboup, Souleymane
Cloherty, Gavin A
author_facet Rodgers, Mary A
Olivo, Ana
Harris, Barbara J
Lark, Chris
Luo, Xinxin
Berg, Michael G
Meyer, Todd V
Mohaimani, Aurash
Orf, Gregory S
Goldstein, Yitz
Fox, Amy S
Hirschhorn, Julie
Glen, William B
Nolte, Frederick
Landay, Alan
Jennings, Cheryl
Moy, James
Servellita, Venice
Chiu, Charles
Batra, Rahul
Snell, Luke B
Nebbia, Gaia
Douthwaite, Sam
Tanuri, Amilcar
Singh, Lavanya
de Oliveira, Tulio
Ahouidi, Ambroise
Mboup, Souleymane
Cloherty, Gavin A
author_sort Rodgers, Mary A
collection PubMed
description BACKGROUND: : Viral diversity presents an ongoing challenge for diagnostic tests, which need to accurately detect all circulating variants. The Abbott Global Surveillance program monitors severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants and their impact on diagnostic test performance. OBJECTIVES: : To evaluate the capacity of Abbott molecular, antigen, and serologic assays to detect circulating SARS-CoV-2 variants, including all current variants of concern (VOC): B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma) and B.1.617.2 (delta). STUDY DESIGN: : Dilutions of variant virus cultures (B.1.1.7, B.1.351, B.1.429, B.1.526.1, B.1.526.2, B.1.617.1, B.1.617.2, P.1, R.1 and control isolate WA1) and a panel of N = 248 clinical samples from patients with sequence confirmed variant infections (B.1.1.7, B.1.351, B.1.427, B.1.429, B.1.526, B.1.526.1, B.1.526.2, P.1, P.2, R.1) were evaluated on at least one assay: Abbott ID NOW COVID-19, m2000 RealTime SARS-CoV-2, Alinity m SARS-CoV-2, and Alinity m Resp-4-Plex molecular assays; the BinaxNOW COVID-19 Ag Card and Panbio COVID-19 Ag Rapid Test Device; and the ARCHITECT/Alinity i SARS-CoV-2 IgG and AdviseDx IgM assays, Panbio COVID-19 IgG assay, and ARCHITECT/Alinity i AdviseDx SARS-CoV-2 IgG II assay. RESULTS: : Consistent with in silico predictions, each molecular and antigen assay detected VOC virus cultures with equivalent sensitivity to the WA1 control strain. Notably, 100% of all tested variant patient specimens were detected by molecular assays (N = 197 m2000, N = 88 Alinity m, N = 99 ID NOW), and lateral flow assays had a sensitivity of >94% for specimens with genome equivalents (GE) per device above 4 log (85/88, Panbio; 54/57 Binax). Furthermore, Abbott antibody assays detected IgG and IgM in 94–100% of sera from immune competent B.1.1.7 patients 15–26 days after symptom onset. CONCLUSIONS: : These data confirm variant detection for 11 SARS-CoV-2 assays, which is consistent with each assay target region being highly conserved. Importantly, alpha, beta, gamma, and delta VOCs were detected by molecular and antigen assays, indicating that these tests may be suitable for widescale use where VOCs predominate.
format Online
Article
Text
id pubmed-8770247
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Abbott Laboratories. Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-87702472022-01-20 Detection of SARS-CoV-2 variants by Abbott molecular, antigen, and serological tests Rodgers, Mary A Olivo, Ana Harris, Barbara J Lark, Chris Luo, Xinxin Berg, Michael G Meyer, Todd V Mohaimani, Aurash Orf, Gregory S Goldstein, Yitz Fox, Amy S Hirschhorn, Julie Glen, William B Nolte, Frederick Landay, Alan Jennings, Cheryl Moy, James Servellita, Venice Chiu, Charles Batra, Rahul Snell, Luke B Nebbia, Gaia Douthwaite, Sam Tanuri, Amilcar Singh, Lavanya de Oliveira, Tulio Ahouidi, Ambroise Mboup, Souleymane Cloherty, Gavin A J Clin Virol Paper from the 21st ESCV meeting BACKGROUND: : Viral diversity presents an ongoing challenge for diagnostic tests, which need to accurately detect all circulating variants. The Abbott Global Surveillance program monitors severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants and their impact on diagnostic test performance. OBJECTIVES: : To evaluate the capacity of Abbott molecular, antigen, and serologic assays to detect circulating SARS-CoV-2 variants, including all current variants of concern (VOC): B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma) and B.1.617.2 (delta). STUDY DESIGN: : Dilutions of variant virus cultures (B.1.1.7, B.1.351, B.1.429, B.1.526.1, B.1.526.2, B.1.617.1, B.1.617.2, P.1, R.1 and control isolate WA1) and a panel of N = 248 clinical samples from patients with sequence confirmed variant infections (B.1.1.7, B.1.351, B.1.427, B.1.429, B.1.526, B.1.526.1, B.1.526.2, P.1, P.2, R.1) were evaluated on at least one assay: Abbott ID NOW COVID-19, m2000 RealTime SARS-CoV-2, Alinity m SARS-CoV-2, and Alinity m Resp-4-Plex molecular assays; the BinaxNOW COVID-19 Ag Card and Panbio COVID-19 Ag Rapid Test Device; and the ARCHITECT/Alinity i SARS-CoV-2 IgG and AdviseDx IgM assays, Panbio COVID-19 IgG assay, and ARCHITECT/Alinity i AdviseDx SARS-CoV-2 IgG II assay. RESULTS: : Consistent with in silico predictions, each molecular and antigen assay detected VOC virus cultures with equivalent sensitivity to the WA1 control strain. Notably, 100% of all tested variant patient specimens were detected by molecular assays (N = 197 m2000, N = 88 Alinity m, N = 99 ID NOW), and lateral flow assays had a sensitivity of >94% for specimens with genome equivalents (GE) per device above 4 log (85/88, Panbio; 54/57 Binax). Furthermore, Abbott antibody assays detected IgG and IgM in 94–100% of sera from immune competent B.1.1.7 patients 15–26 days after symptom onset. CONCLUSIONS: : These data confirm variant detection for 11 SARS-CoV-2 assays, which is consistent with each assay target region being highly conserved. Importantly, alpha, beta, gamma, and delta VOCs were detected by molecular and antigen assays, indicating that these tests may be suitable for widescale use where VOCs predominate. Abbott Laboratories. Published by Elsevier B.V. 2022-02 2022-01-20 /pmc/articles/PMC8770247/ /pubmed/35086043 http://dx.doi.org/10.1016/j.jcv.2022.105080 Text en © 2022 Abbott Laboratories Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Paper from the 21st ESCV meeting
Rodgers, Mary A
Olivo, Ana
Harris, Barbara J
Lark, Chris
Luo, Xinxin
Berg, Michael G
Meyer, Todd V
Mohaimani, Aurash
Orf, Gregory S
Goldstein, Yitz
Fox, Amy S
Hirschhorn, Julie
Glen, William B
Nolte, Frederick
Landay, Alan
Jennings, Cheryl
Moy, James
Servellita, Venice
Chiu, Charles
Batra, Rahul
Snell, Luke B
Nebbia, Gaia
Douthwaite, Sam
Tanuri, Amilcar
Singh, Lavanya
de Oliveira, Tulio
Ahouidi, Ambroise
Mboup, Souleymane
Cloherty, Gavin A
Detection of SARS-CoV-2 variants by Abbott molecular, antigen, and serological tests
title Detection of SARS-CoV-2 variants by Abbott molecular, antigen, and serological tests
title_full Detection of SARS-CoV-2 variants by Abbott molecular, antigen, and serological tests
title_fullStr Detection of SARS-CoV-2 variants by Abbott molecular, antigen, and serological tests
title_full_unstemmed Detection of SARS-CoV-2 variants by Abbott molecular, antigen, and serological tests
title_short Detection of SARS-CoV-2 variants by Abbott molecular, antigen, and serological tests
title_sort detection of sars-cov-2 variants by abbott molecular, antigen, and serological tests
topic Paper from the 21st ESCV meeting
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770247/
https://www.ncbi.nlm.nih.gov/pubmed/35086043
http://dx.doi.org/10.1016/j.jcv.2022.105080
work_keys_str_mv AT rodgersmarya detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests
AT olivoana detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests
AT harrisbarbaraj detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests
AT larkchris detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests
AT luoxinxin detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests
AT bergmichaelg detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests
AT meyertoddv detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests
AT mohaimaniaurash detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests
AT orfgregorys detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests
AT goldsteinyitz detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests
AT foxamys detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests
AT hirschhornjulie detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests
AT glenwilliamb detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests
AT noltefrederick detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests
AT landayalan detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests
AT jenningscheryl detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests
AT moyjames detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests
AT servellitavenice detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests
AT chiucharles detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests
AT batrarahul detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests
AT snelllukeb detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests
AT nebbiagaia detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests
AT douthwaitesam detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests
AT tanuriamilcar detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests
AT singhlavanya detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests
AT deoliveiratulio detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests
AT ahouidiambroise detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests
AT mboupsouleymane detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests
AT clohertygavina detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests